Ekso Bionics Delivers Third Quarter Financial Results
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), a leader in exoskeleton technology for both medical and industrial applications, has shared its financial performance for the third quarter of the year. The report reveals notable revenue figures and key operational accomplishments that reflect the company's ongoing focus on enhancing mobility for individuals with disabilities.
Revenue and Sales Growth
For the third quarter of 2024, Ekso Bionics reported a revenue of $4.1 million. This represents a slight decline from $4.6 million reported for the same quarter last year. The company also sold a commendable total of 33 EksoHealth devices during this period, showcasing continued demand for its innovative products.
Noteworthy Achievements
One remarkable achievement in this quarter was the receipt of initial reimbursement approval from the Centers for Medicare & Medicaid Services (CMS) for the Ekso Indego Personal. This significant milestone is expected to enhance access for spinal cord injury patients relying on Medicare, allowing them to use this transformative technology in both home and community settings.
Financial Overview
The gross profit for the quarter was reported at $2.2 million, which corresponds to a gross margin of approximately 53.5%. This marks a minor increase from the previous year's gross margin of 53.3%. Cost-saving measures in the supply chain, coupled with a slight reduction in service costs, were instrumental in achieving this improvement, despite a decline attributed to lower margin sales from increased distribution volume.
Strategic Financial Management
Sales and marketing expenses totaled $1.8 million, reflecting a 14% reduction compared to last year's $2.1 million. Such a decrease was primarily due to adjustments in headcount and reduced discretionary expenses including payroll and travel. Similarly, research and development costs came down to $0.8 million from $1.2 million the prior year, primarily due to decreased reliance on product development consultants.
Long-Term Outlook and Future Endeavors
Net loss applicable to common stockholders for Q3 2024 narrowed down to $2.1 million, translating to a loss of $0.10 per basic and diluted share. This is a considerable improvement from the net loss of $3.4 million or $0.24 per share reported for the same quarter last year. Such financial prudence indicates significant strides in managing operational expenditures while being conducive to future growth.
Cash Position
As of the end of September 2024, Ekso Bionics held $8.3 million in cash, a minor decrease from $8.6 million at the end of 2023. The company successfully closed a public offering in September that provided approximately $5.0 million in net proceeds, supporting its financial stability.
Investors Engagement
In addition to the financial results, management hosted a conference call to discuss the company's latest business developments. Investors could participate through the company’s official website, enhancing transparency and engagement with stakeholders.
About Ekso Bionics
Founded in 2005, Ekso Bionics has established itself as a forefront innovator in exoskeleton solutions designed to amplify human capability, providing critical mobility support across medical and industrial fields. Its groundbreaking technologies continue to evolve, empowering those with mobility challenges to achieve greater independence and quality of life.
Frequently Asked Questions
What was the total revenue reported for Q3 2024 by Ekso Bionics?
Ekso Bionics reported a total revenue of $4.1 million for the third quarter of 2024.
How many devices were sold in the third quarter?
The company sold 33 EksoHealth devices during the third quarter.
What reimbursement did Ekso Bionics receive this quarter?
They received initial reimbursement approval from CMS for the Ekso Indego Personal.
What was the gross profit for the third quarter?
Ekso Bionics achieved a gross profit of $2.2 million, with a gross margin of approximately 53.5%.
What is the company's mission?
Ekso Bionics aims to enhance human potential by developing exoskeleton technology that supports strength, endurance, and mobility.
